Invicta Diagnostic Limited Appoints New Director and Approves Transactions
Mumbai – March 25, 2026 – Invicta Diagnostic Limited announced several key developments following a board meeting held on Wednesday, March 25, 2026.The company appointed Mr. Rohit Prakash Srivastava (DIN: 01432112) as an Additional Director, effective immediately. He has also been appointed as Whole Time Director-Finance for a period of 5 consecutive years, pending shareholder approval at the ensuing Extraordinary General Meeting. Mr. Srivastava brings over 19 years of experience across various industries, including investment banking, education, wealth management, and healthcare. His spouse, Ms. Konica Srivastava, is a manager at the company. He will receive an annual remuneration of Rs. 7.20 Lakhs, along with perquisites as provided under the Companies Act, 2013.
The board also approved material related-party transactions with PCD Diagnostics LLP, Pratham MRI and CT Scan Centre, Primacare Healthcare LLP, Invicta Medical LLP, Primacare Diagnostic LLP, Mscribeit Infotech LLP, Porteus Medical LLP, Invicta Diagnostic Lifecare LLP, Invicta Diagnostic Healthplus LLP, and Shegaon Diagnostic LLP, subject to shareholder approval. Additionally, related-party transactions were approved involving Ms. Komal Sanket Jain, Ms. Garima Naredi, Ms. Aditi Jayesh Jain, and Ms. Payal Kunal Jain.
Further, the board approved changes, deviations, and variations to the objects and utilization of funds from the Initial Public Offering (IPO) proceeds. This includes establishing diagnostic centers at promising locations, selecting technologically advanced medical equipment, and optimizing capital deployment.
The approved changes to the IPO proceeds allocation are detailed below:
| Sr. No. | Original Object | Total Amount Raised (Rs. in Lakhs) | Amount Reallocated (Rs. in Lakhs) | Details of Variation / Deviation | Amount reallocated for Object NO.3 (Rs. in Lakhs) | Revised Timeline for Utilization | Revised Timeline for Utilization |
|---|---|---|---|---|---|---|---|
| 1 | Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra | 2,111.33 | 1351.33* | The company proposes to commence at least five diagnostic centers in Maharashtra directly or through subsidiary entities, including Diagnostic Centre at Object No. 3. Details of New Object, variation and deviation are provided. | 760.00 (to be utilized for New Object No. 3) | Up March 2027 | Up March 2027 |
| 2 | General Corporate Purposes | 407.46 | 422.56** | Rs. 15.10 lakhs remained after payment of Issue related Expenses is reallocated towards expenses for General Corporate Purpose. | NIL | Up March 2027 | Up March 2027 |
| 3 | New Object: Nashik Centre - Acquisition of up to 95% stake | - | 760.00 | New Object to be funded out of revised unutilized amount from Object No. 1. | Up March 2027 | Up March 2027 |
* Rs. 1351.33 Lakh includes Rs. 227.79 Lakhs already utilized for machinery purchase.
** Rs. 422.56 includes General Corporate Purpose expenses paid till date of Rs. 238 Lakhs.
The board also approved the acquisition of up to 95% stake in Vinchurkar Diagnostics Private Limited for a cash consideration of Rs. 760.00 Lakhs, subject to shareholder approval.
A notice has been issued for an Extraordinary General Meeting of shareholders to be held on Friday, April 17, 2026, at 11:00 AM (IST) via Video Conferencing/Other Audio Visual Means facility.
Sanket Vinod Jain, Chairman and Non-Executive Director (DIN: 08299039), signed off on the announcements.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.